serious rerating ahead

i have posted the link to the article i am refering to at the end. some salient points:

1. 'First large scale rollout of Ovplex' - this is a new beginning and its never been marketed at this scale before. so past is no indicator.. its up and away from here on.

2. 'significant share' - Intus Healthcare is targeting a significant share of the 750,000 annual UK tests - and i am guessing that implies a number closer to 50% than say 10%... and that implies an MC of close to $300 Million based on UK sales alone.

3.European Certification - paving the way to market across Europe.

4.$70 per test... cant overemphasize this number!!!

5.Opened discussions with Korea, China and European countries.

6.'Approached' by central south american countries - APPROACHED! - they want it!

7. 'strong commercial upside' !! - based on the approach and 'Product of the Year in Asia Pacific for 2010'

cant think of any other bio stock that can boast these numbers and potential markets and yet stay sub $20Mill in MC!... this MC is a joke... dont regret not holding when you had the chance :)

http://www.menafn.com/qn_news_story_s.asp?storyid=1093308062